Efficacy and Safety of Psychedelics in Treating Anxiety Disorders

REFERENCES

1. 1.↵
   1. Bandelow B,
   2. Michaelis S

   . Epidemiology of anxiety disorders in the 21st century. Dialogues Clin Neurosci. 2015;17(3):327-335. doi: 10.31887/DCNS.2015.17.3/bbandelow

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Waghorn G,
   2. Chant D,
   3. White P,
   4. Whiteford H

   . Disability, employment and work performance among people with ICD-10 anxiety disorders. Aust N Z J Psychiatry. 2005;39(1-2):55-66. doi: 10.1080/j.1440-1614.2005.01510.x

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Kessler RC,
   2. Petukhova M,
   3. Sampson NA,
   4. Zaslavsky AM,
   5. Wittchen HU

   . Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res. 2012;21(3):169-184. doi: 10.1002/mpr.1359

   OpenUrlCrossRefPubMed
4. 4.↵
   American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, DSM-5-TR. 5th ed. Text revision. American Psychiatric Association; 2022.
5. 5.↵
   1. Bystritsky A,
   2. Khalsa SS,
   3. Cameron ME,
   4. Schiffman J

   . Current diagnosis and treatment of anxiety disorders. P T. 2013;38(1):30-57.

   OpenUrl
6. 6.↵
   1. Chand SP,
   2. Marwaha R

   . Anxiety. In: StatPearls. Treasure Island (FL): StatPearls Publishing; April 24, 2023.
7. 7.↵
   1. Olatunji BO,
   2. Cisler JM,
   3. Tolin DF

   . Quality of life in the anxiety disorders: a meta-analytic review. Clin Psychol Rev. 2007;27(5):572-581. doi: 10.1016/j.cpr.2007.01.015

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Wittchen HU

   . Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety. 2002;16(4):162-171. doi: 10.1002/da.10065

   OpenUrlCrossRefPubMedWeb of Science
9. 9.↵
   1. DuPont RL,
   2. Rice DP,
   3. Miller LS,
   4. Shiraki SS,
   5. Rowland CR,
   6. Harwood HJ

   . Economic costs of anxiety disorders. Anxiety. 1996;2(4):167-172. doi: 10.1002/(SICI)1522-7154(1996)2:4<167::AID-ANXI2>3.0.CO;2-L

   OpenUrlCrossRefPubMedWeb of Science
10. 10.↵
    1. Beesdo-Baum K,
    2. Knappe S,
    3. Fehm L,
    4. et al.

    The natural course of social anxiety disorder among adolescents and young adults. Acta Psychiatr Scand. 2012;126(6):411-425. doi: 10.1111/j.1600-0447.2012.01886.x

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Yonkers KA,
    2. Dyck IR,
    3. Warshaw M,
    4. Keller MB

    . Factors predicting the clinical course of generalised anxiety disorder. Br J Psychiatry. 2000;176:544-549. doi: 10.1192/bjp.176.6.544

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Noyes R Jr.

    Comorbidity in generalized anxiety disorder. Psychiatr Clin North Am. 2001;24(1):41-55. doi: 10.1016/s0193-953x(05)70205-7

    OpenUrlCrossRefPubMedWeb of Science
13. 13.↵
    1. Meuret AE,
    2. Tunnell N,
    3. Roque A

    . Anxiety disorders and medical comorbidity: treatment implications. Adv Exp Med Biol. 2020;1191:237-261. doi: 10.1007/978-981-32-9705-0_15

    OpenUrlCrossRef
14. 14.↵
    1. Bystritsky A

    . Treatment-resistant anxiety disorders. Mol Psychiatry. 2006;11(9):805-814. doi: 10.1038/sj.mp.4001852

    OpenUrlCrossRefPubMedWeb of Science
15. 15.↵
    1. Ferguson JM

    . SSRI antidepressant medications: adverse effects and tolerability. Prim Care Companion J Clin Psychiatry. 2001;3(1):22-27. doi: 10.4088/pcc.v03n0105

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Stein DJ

    . Evidence-based pharmacotherapy of generalised anxiety disorder: focus on agomelatine. Adv Ther. 2021;38(Suppl 2):52-60. doi: 10.1007/s12325-021-01860-1

    OpenUrlCrossRefPubMed
17. 17.↵
    1. Westra HA

    . Managing resistance in cognitive behavioural therapy: the application of motivational interviewing in mixed anxiety and depression. Cogn Behav Ther. 2004;33(4):161-175. doi: 10.1080/16506070410026426

    OpenUrlCrossRefPubMed
18. 18.↵
    1. Wolitzky-Taylor K,
    2. Fenwick K,
    3. Lengnick-Hall R,
    4. et al.

    A preliminary exploration of the barriers to delivering (and receiving) exposure-based cognitive behavioral therapy for anxiety disorders in adult community mental health settings. Community Ment Health J. 2018;54(7):899-911. doi: 10.1007/s10597-018-0252-x

    OpenUrlCrossRef
19. 19.↵
    1. Melaragno AJ

    . Pharmacotherapy for anxiety disorders: from first-line options to treatment resistance. Focus (Am Psychiatr Publ). 2021;19(2):145-160. doi: 10.1176/appi.focus.20200048

    OpenUrlCrossRef
20. 20.↵
    1. Ansara ED

    . Management of treatment-resistant generalized anxiety disorder. Ment Health Clin. 2020;10(6):326-334. doi: 10.9740/mhc.2020.11.326

    OpenUrlCrossRef
21. 21.↵
    1. Nemeroff CB

    , ed. Management of Treatment-Resistant Major Psychiatric Disorders. Oxford University Press; 2012.
22. 22.↵
    1. Marasine NR,
    2. Sankhi S

    . Factors associated with antidepressant medication non-adherence. Turk J Pharm Sci. 2021;18(2):242-249. doi: 10.4274/tjps.galenos.2020.49799

    OpenUrlCrossRef
23. 23.↵
    1. Nutt D

    . Psychedelic drugs–a new era in psychiatry? Dialogues Clin Neurosci. 2019;21(2):139-147. doi: 10.31887/DCNS.2019.21.2/dnutt

    OpenUrlCrossRefPubMed
24. 24.↵
    1. Nichols DE

    . Hallucinogens. Pharmacol Ther. 2004;101(2):131-181. doi: 10.1016/j.pharmthera.2003.11.002

    OpenUrlCrossRefPubMedWeb of Science
25. 25.↵
    1. Freye E

    . Peyote, a mescaline-containing cactus. In: Pharmacology and Abuse of Cocaine, Amphetamines, Ecstasy and Related Designer Drugs. A Comprehensive Review on their Mode of Action, Treatment of Abuse and Intoxication. Springer; 2010: 227-228.
26. 26.↵
    1. Guerra-Doce E

    . Psychoactive substances in prehistoric times: examining the archaeological evidence. Time Mind. 2015;8(1):91-112. doi: 10.1080/1751696X.2014.993244

    OpenUrlCrossRef
27. 27.↵
    1. Wexler P

    1. Hoffman MA

    . Entheogens (phychedelic drugs) and the ancient mystery religions. In: Wexler P, ed. Toxicology in Antiquity. A Volume in History of Toxicology and Environement Health. 2nd ed. Academic Press; 2019:353-362.
28. 28.↵
    1. Hofmann A

    . How LSD originated. J Psychedelic Drugs. 1979;11(1-2):53-60. doi: 10.1080/02791072.1979.10472092

    OpenUrlCrossRefPubMed
29. 29.↵
    1. Vollenweider FX,
    2. Preller KH

    . Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. Nat Rev Neurosci. 2020;21(11):611-624. doi: 10.1038/s41583-020-0367-2

    OpenUrlCrossRefPubMed
30. 30.↵
    1. Nichols DE,
    2. Walter H

    . The history of psychedelics in psychiatry. Pharmacopsychiatry. 2021;54(4):151-166. doi: 10.1055/a-1310-3990

    OpenUrlCrossRefPubMed
31. 31.↵
    1. Oram M

    . The Trials of Psychedelic Therapy: LSD Pscychotherapy in America. Johns Hopkins University Press; 2018.
32. 32.↵
    1. Chi T,
    2. Gold JA

    . A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses. J Neurol Sci. 2020;411:116715. doi: 10.1016/j.jns.2020.116715

    OpenUrlCrossRef
33. 33.↵
    1. Passie T

    . Psycholytic and Psychedelic Therapy Research 1931-1995: A Complete International Bibliography. Laurentius Publishers; 1997.
34. 34.↵
    1. Drug scheduling

    . United States Drug Enforcement Administration. Accessed May 25, 2023. dea.gov/drug-information/drug-scheduling
35. 35.↵
    1. Pilecki B,
    2. Luoma JB,
    3. Bathje GJ,
    4. Rhea J,
    5. Narloch VF

    . Ethical and legal issues in psychedelic harm reduction and integration therapy. Harm Reduct J. 2021;18(1):40. doi: 10.1186/s12954-021-00489-1

    OpenUrlCrossRef
36. 36.
    1. Shulgin A,
    2. Shulgin A

    . PiHKAL: A Chemical Love Story. Transform Press; 1991.
37. 37.↵
    1. Shulgin A,
    2. Shulgin A

    . TiHKAL: The Continuation. Transform Press; 1997.
38. 38.↵
    1. Vollenweider FX,
    2. Kometer M

    . The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci. 2010;11(9):642-651. doi: 10.1038/nrn2884

    OpenUrlCrossRefPubMed
39. 39.↵
    1. Preller KH,
    2. Burt JB,
    3. Ji JL,
    4. et al.

    Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor. Elife. 2018;7:e35082. doi: 10.7554/eLife.35082

    OpenUrlCrossRef
40. 40.
    1. Vollenweider FX,
    2. Vollenweider-Scherpenhuyzen MF,
    3. Bäbler A,
    4. Vogel H,
    5. Hell D

    . Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport. 1998;9(17):3897-3902. doi: 10.1097/00001756-199812010-00024

    OpenUrlCrossRefPubMedWeb of Science
41. 41.↵
    1. Nichols DE

    . Psychedelics [published correction appears in Pharmacol Rev. 2016 Apr;68(2):356]. Pharmacol Rev. 2016;68(2):264-355. doi: 10.1124/pr.115.011478

    OpenUrlAbstract/FREE Full Text
42. 42.↵
    1. Ray TS

    . Psychedelics and the human receptorome [published correction appears in PLoS One. 2010;5(3). doi: 10.1371/annotation/e580a864-cf13-40c2-9bd9-b9687a6f0fe4]. PLoS One. 2010;5(2):e9019. doi:doi: 10.1371/journal.pone.0009019

    OpenUrlCrossRefPubMed
43. 43.↵
    1. Mendes FR,
    2. dos Santos Costa C,
    3. Wiltenburg VD,
    4. Morales-Lima G,
    5. Fernandes JAB,
    6. Filev R

    . Classic and non-classic psychedelics for substance use disorder: a review of their historic, past and current research. Addict Neurosci. 2022;3:100025. doi: 10.1016/j.addicn.2022.100025

    OpenUrlCrossRef
44. 44.↵
    1. Papaseit E,
    2. Farré M,
    3. Pérez-Mañá C,
    4. et al.

    Acute pharmacological effects of 2C-B in humans: an observational study. Front Pharmacol. 2018;9:206. doi: 10.3389/fphar.2018.00206

    OpenUrlCrossRef
45. 45.↵
    1. Nardou R,
    2. Sawyer E,
    3. Song YJ,
    4. et al.

    Psychedelics reopen the social reward learning critical period. Nature. 2023;618(7966):790-798. doi: 10.1038/s41586-023-06204-3

    OpenUrlCrossRef
46. 46.↵
    1. Davis AK,
    2. Barrett FS,
    3. Griffiths RR

    . Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety. J Contextual Behav Sci. 2020;15:39-45. doi: 10.1016/j.jcbs.2019.11.004

    OpenUrlCrossRefPubMed
47. 47.↵
    1. Lebedev AV,
    2. Lövdén M,
    3. Rosenthal G,
    4. Feilding A,
    5. Nutt DJ,
    6. Carhart-Harris RL

    . Finding the self by losing the self: neural correlates of ego-dissolution under psilocybin. Hum Brain Mapp. 2015;36(8):3137-3153. doi: 10.1002/hbm.22833

    OpenUrlCrossRefPubMed
48. 48.↵
    1. Letheby C,
    2. Gerrans P

    . Self unbound: ego dissolution in psychedelic experience. Neurosci Conscious. 2017;2017(1):nix016. doi: 10.1093/nc/nix016

    OpenUrlCrossRef
49. 49.↵
    1. Stoliker D,
    2. Egan GF,
    3. Friston KJ,
    4. Razi A

    . Neural mechanisms and psychology of psychedelic ego dissolution. Pharmacol Rev. 2022;74(4):876-917. doi: 10.1124/pharmrev.121.000508

    OpenUrlAbstract/FREE Full Text
50. 50.↵
    National Institute on Drug Abuse. MDMA (ecstasy/molly) drugfacts. U.S. Department of Health and Human Services, National Institutes of Health. Published June 2020. Accessed November 10, 2023. nida.nih.gov/publications/drugfacts/mdma-ecstasymolly
51. 51.↵
    1. Bedi G,
    2. Hyman D,
    3. de Wit H

    . Is ecstasy an “empathogen”? Effects of ±3,4-methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in others. Biol Psychiatry. 2010;68(12):1134-1140. doi: 10.1016/j.biopsych.2010.08.003

    OpenUrlCrossRefPubMedWeb of Science
52. 52.↵
    1. Mithoefer MC,
    2. Wagner MT,
    3. Mithoefer AT,
    4. Jerome L,
    5. Doblin R

    . The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study [published correction appears in J Psychopharmacol. 2011 Jun;25(6):852]. J Psychopharmacol. 2011;25(4):439-452. doi: 10.1177/0269881110378371

    OpenUrlCrossRefPubMedWeb of Science
53. 53.↵
    1. Liu GL,
    2. Cui YF,
    3. Lu C,
    4. Zhao P

    . Ketamine a dissociative anesthetic: neurobiology and biomolecular exploration in depression. Chem Biol Interact. 2020;319:109006. doi: 10.1016/j.cbi.2020.109006

    OpenUrlCrossRef
54. 54.↵
    1. Berman RM,
    2. Cappiello A,
    3. Anand A,
    4. et al.

    Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351-354. doi: 10.1016/s0006-3223(99)00230-9

    OpenUrlCrossRefPubMedWeb of Science
55. 55.↵
    1. Roth BL,
    2. Baner K,
    3. Westkaemper R,
    4. et al.

    Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci U S A. 2002;99(18):11934-11939. doi: 10.1073/pnas.182234399

    OpenUrlAbstract/FREE Full Text
56. 56.↵
    1. Taylor GT,
    2. Manzella F

    . Kappa opioids, salvinorin A and major depressive disorder. Curr Neuropharmacol. 2016;14(2):165-176. doi: 10.2174/1570159x13666150727220944

    OpenUrlCrossRefPubMed
57. 57.↵
    1. Jacobs A

    . Legal use of hallucinogenic mushrooms begins in Oregon. The Seattle Times. Published and updated January 3, 2023. Accessed October 2, 2023. seattletimes.com/nation-world/legal-use-of-hallucinogenic-mushrooms-begins-in-oregon/
58. 58.↵
    The Department of Health and Aged Care: Therapeutic Goods Administration. MDMA and psilocybin hub. Australian Government. Accessed May 19, 2023. tga.gov.au/products/unapproved-therapeutic-goods/mdma-and-psilocybin-hub
59. 59.↵
    1. Siegel JS,
    2. Daily JE,
    3. Perry DA,
    4. Nicol GE

    . Psychedelic drug legislative reform and legalization in the US. JAMA Psychiatry. 2023;80(1):77-83. doi: 10.1001/jamapsychiatry.2022.4101

    OpenUrlCrossRef
60. 60.↵
    1. Page MJ,
    2. McKenzie JE,
    3. Bossuyt PM,
    4. et al.

    The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71

    OpenUrlFREE Full Text
61. 61.↵
    1. Higgins JP,
    2. Altman DG,
    3. Gøtzsche PC,
    4. et al.

    The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. doi: 10.1136/bmj.d5928

    OpenUrlFREE Full Text
62. 62.↵
    1. Glue P,
    2. Medlicott NJ,
    3. Harland S,
    4. et al.

    Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. J Psychopharmacol. 2017;31(10):1302-1305. doi: 10.1177/0269881117705089

    OpenUrlCrossRef
63. 63.↵
    1. Glue P,
    2. Neehoff SM,
    3. Medlicott NJ,
    4. Gray A,
    5. Kibby G,
    6. McNaughton N

    . Safety and efficacy of maintenance ketamine treatment in patients with treatment-refractory generalised anxiety and social anxiety disorders. J Psychopharmacol. 2018;32(6):663-667. doi: 10.1177/0269881118762073

    OpenUrlCrossRef
64. 64.↵
    1. Glue P,
    2. Neehoff S,
    3. Sabadel A,
    4. et al.

    Effects of ketamine in patients with treatment-refractory generalized anxiety and social anxiety disorders: exploratory double-blind psychoactive-controlled replication study. J Psychopharmacol. 2020;34(3):267-272. doi: 10.1177/0269881119874457

    OpenUrlCrossRef
65. 65.↵
    1. Wolfson PE,
    2. Andries J,
    3. Feduccia AA,
    4. et al.

    MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study. Sci Rep. 2020;10(1):20442. doi: 10.1038/s41598-020-75706-1

    OpenUrlCrossRef
66. 66.↵
    1. Gasser P,
    2. Kirchner K,
    3. Passie T

    . LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects. J Psychopharmacol. 2015;29(1):57-68. doi: 10.1177/0269881114555249

    OpenUrlCrossRefPubMed
67. 67.↵
    1. Gasser P,
    2. Holstein D,
    3. Michel Y,
    4. et al.

    Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis. 2014;202(7):513-520. doi: 10.1097/NMD.0000000000000113

    OpenUrlCrossRefPubMed
68. 68.↵
    1. Taylor JH,
    2. Landeros-Weisenberger A,
    3. Coughlin C,
    4. et al.

    Ketamine for social anxiety disorder: a randomized, placebo-controlled crossover trial. Neuropsychopharmacology. 2018;43(2):325-333. doi: 10.1038/npp.2017.194

    OpenUrlCrossRef
69. 69.↵
    1. Grob CS,
    2. Danforth AL,
    3. Chopra GS,
    4. et al.

    Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry. 2011;68(1):71-78. doi: 10.1001/archgenpsychiatry.2010.116

    OpenUrlCrossRefPubMedWeb of Science
70. 70.↵
    1. Dos Santos RG,
    2. Osório FL,
    3. Rocha JM

    , et al. Ayahuasca improves self-perception of speech performance in subjects with social anxiety disorder: a pilot, proof-of-concept, randomized, placebo-controlled trial. J Clin Psychopharmacol. 2021;41(5):540-550. doi: 10.1097/JCP.0000000000001428

    OpenUrlCrossRef
71. 71.↵
    1. Zarate CA Jr.,
    2. Singh JB,
    3. Carlson PJ,
    4. et al.

    A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856-864. doi: 10.1001/archpsyc.63.8.856

    OpenUrlCrossRefPubMedWeb of Science
72. 72.↵
    1. Yavi M,
    2. Lee H,
    3. Henter ID,
    4. Park LT,
    5. Zarate CA Jr.

    Ketamine treatment for depression: a review. Discov Ment Health. 2022;2(1):9. doi: 10.1007/s44192-022-00012-3

    OpenUrlCrossRef
73. 73.↵
    1. Shelton RC

    . Serotonin and norepinephrine reuptake inhibitors. Handb Exp Pharmacol. 2019;250:145-180. doi: 10.1007/164_2018_164

    OpenUrlCrossRef
74. 74.↵
    1. Bandelow B,
    2. Michaelis S,
    3. Wedekind D

    . Treatment of anxiety disorders. Dialogues Clin Neurosci. 2017;19(2):93-107. doi: 10.31887/DCNS.2017.19.2/bbandelow

    OpenUrlCrossRef
75. 75.↵
    1. Nichols DE,
    2. Grob CS

    . Is LSD toxic? Forensic Sci Int. 2018;284:141-145. doi: 10.1016/j.forsciint.2018.01.006

    OpenUrlCrossRefPubMed
76. 76.↵
    1. Winkelman M

    . Psychedelics as medicines for substance abuse rehabilitation: evaluating treatments with LSD, peyote, ibogaine and ayahuasca. Curr Drug Abuse Rev. 2014;7(2):101-116. doi: 10.2174/1874473708666150107120011

    OpenUrlCrossRefPubMed
77. 77.↵
    1. Talin P,
    2. Sanabria E

    . Ayahuasca's entwined efficacy: an ethnographic study of ritual healing from ‘addiction’. Int J Drug Policy. 2017;44:23-30. doi: 10.1016/j.drugpo.2017.02.017

    OpenUrlCrossRef
78. 78.↵
    National Institute on Drug Abuse. MDMA (ecstasy) abuse research report: is MDMA addictive? U.S. Department of Health and Human Services, National Institutes of Health. Published September 2017. Accessed August 13, 2023. nida.nih.gov/publications/research-reports/mdma-ecstasy-abuse/mdma-addictive
79. 79.↵
    1. Cottler LB,
    2. Womack SB,
    3. Compton WM,
    4. Ben-Abdallah A

    . Ecstasy abuse and dependence among adolescents and young adults: applicability and reliability of DSM-IV criteria. Hum Psychopharmacol. 2001;16(8):599-606. doi: 10.1002/hup.343

    OpenUrlCrossRefPubMedWeb of Science
80. 80.↵
    1. Simmler LD,
    2. Li Y,
    3. Hadjas LC,
    4. Hiver A,
    5. van Zessen R,
    6. Lüscher C

    . Dual action of ketamine confines addiction liability. Nature. 2022;608(7922):368-373. doi: 10.1038/s41586-022-04993-7

    OpenUrlCrossRefPubMed
81. 81.↵
    1. Kokane SS,
    2. Armant RJ,
    3. Bolaños-Guzmán CA,
    4. Perrotti LI

    . Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant. Behav Brain Res. 2020;384:112548. doi: 10.1016/j.bbr.2020.112548

    OpenUrlCrossRef
82. 82.↵
    1. Cottler LB,
    2. Leung KS,
    3. Abdallah AB

    . Test-re-test reliability of DSM-IV adopted criteria for 3,4-methylenedioxymethamphetamine (MDMA) abuse and dependence: a cross-national study. Addiction. 2009;104(10):1679-1690. doi: 10.1111/j.1360-0443.2009.02649.x

    OpenUrlCrossRefPubMed
83. 83.↵
    1. McKetin R,
    2. Copeland J,
    3. Norberg MM,
    4. Bruno R,
    5. Hides L,
    6. Khawar L

    . The effect of the ecstasy ‘come-down’ on the diagnosis of ecstasy dependence. Drug Alcohol Depend. 2014;139:26-32. doi: 10.1016/j.drugalcdep.2014.02.697

    OpenUrlCrossRef
84. 84.↵
    1. Malcolm B,
    2. Thomas K

    . Serotonin toxicity of serotonergic psychedelics. Psychopharmacology (Berl). 2022;239(6):1881-1891. doi: 10.1007/s00213-021-05876-x

    OpenUrlCrossRef
85. 85.↵
    1. Johnson M,
    2. Richards W,
    3. Griffiths R

    . Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008;22(6):603-620. doi: 10.1177/0269881108093587

    OpenUrlCrossRefPubMedWeb of Science
86. 86.↵
    1. Ungerleider JT,
    2. Fisher DD,
    3. Fuller M,
    4. Caldwell A

    . The “bad trip”—the etiology of the adverse LSD reaction. Am J Psychiatry. 1968;124(11):1483-1490. doi: 10.1176/ajp.124.11.1483

    OpenUrlCrossRefPubMedWeb of Science
87. 87.↵
    1. Krebs TS,
    2. Johansen PØ

    . Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. J Psychopharmacol. 2012;26(7):994-1002. doi: 10.1177/0269881112439253

    OpenUrlCrossRefPubMedWeb of Science
88. 88.↵
    1. Grabski M,
    2. McAndrew A,
    3. Lawn W,
    4. et al.

    Adjunctive ketamine with relapse prevention-based psychological therapy in the treatment of alcohol use disorder. Am J Psychiatry. 2022;179(2):152-162. doi: 10.1176/appi.ajp.2021.21030277

    OpenUrlCrossRef
89. 89.↵
    1. Roberts TB,
    2. Winkelman MJ

    1. Frecska E

    . Therapeutic guidelines: dangers and contra-indications in therapeutic applications of hallucinogens. In: Roberts TB, , Winkelman MJ, eds. Psychedelic Medicine: New Evidence for Hallucinogenic Substances as Treatments. Vol 1. Praeger; 2007: 69-95. doi: 10.13140/RG.2.1.2364.8888

    OpenUrlCrossRef